Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...

Update 3:10pm: Adds analyst comment. Regeneron (NASDAQ:REGN) won a permanent injunction that blocks drugmakers including, ...

Stuart Williams, chief legal officer for Mylan Pharmaceuticals, insists that the FDA decisions violate the Hatch-Waxman Act, and a court challenge seems likely. There's little doubt that the FDA ...

Upate 2:10pm: Adds analyst comment. Regeneron (NASDAQ:REGN) won a temporary restraining order that blocks drugmakers ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Heritage is ponying up $10 million while Apotex is set to pay $39.1 million over the companies’ alleged roles in a sweeping ...

Viatris (VTRS) stock surges after Q3 earnings beat expectations with strong revenue growth and optimistic revenue outlook for ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...

A comparative minnow, Torrent Pharmaceuticals, backed by a clutch of private equity players, also made a surprise bid but ...

Generic drugs make up about 40% of the ... Prior to the formation in 2020, Mylan had a debt balance of roughly $12 billion and the combination of Mylan and Upjohn raised additional $12 billion ...

A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo The number of sexually transmitted ...

Nevertheless, that is less than 6% of total revenues, and in Q2, both generics revenues of $1.42bn ... inherited from Pfizer / Mylan. The company earned ~$1.3bn in Europe in Q2, ~$1bn in the ...